A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Harbour ships CTLA-4 asset to form new biotech in $1.1B biobucks deal
Harbour ships CTLA-4 asset to form new biotech in $1.1B biobucks deal
GSK explores frontiers of siRNA with $1B deal for 2 drugs from Chinese biotech
GSK explores frontiers of siRNA with $1B deal for 2 drugs from Chinese biotech
Labcorp, PathAI expand partnership to offer AI tech for digital pathology diagnostics
Labcorp, PathAI expand partnership to offer AI tech for digital pathology diagnostics
Abcuro's KLRG1 antibody flunks phase 2/3 muscle disease study
Abcuro's KLRG1 antibody flunks phase 2/3 muscle disease study
Allurion stock balloons as FDA signs off on its weight loss gastric system
Allurion stock balloons as FDA signs off on its weight loss gastric system
Medtronic's diabetes business MiniMed eyes $784M IPO
Medtronic's diabetes business MiniMed eyes $784M IPO
Organon pays $27.5M upfront to license Sebela's hormone-free copper IUD
Organon pays $27.5M upfront to license Sebela's hormone-free copper IUD
Galapagos takes €228M hit from cell therapy wind-down but still has cash for dealmaking
Galapagos takes €228M hit from cell therapy wind-down but still has cash for dealmaking
Protara sees 66% 6-month bladder cancer response rate, but drops to 33% at 12 months
Protara sees 66% 6-month bladder cancer response rate, but drops to 33% at 12 months
‘The perfect partner’: Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific
‘The perfect partner’: Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific
Angelini nocks an AI arrow with $120M Quiver Bioscience deal
Angelini nocks an AI arrow with $120M Quiver Bioscience deal
UPDATED: FDA illuminates new approval pathway for bespoke gene editing therapies
UPDATED: FDA illuminates new approval pathway for bespoke gene editing therapies
FDA issues safety alert on Trividia blood glucose monitors
FDA issues safety alert on Trividia blood glucose monitors
Generate plans $425M IPO to bankroll antibody's phase 3 asthma trials
Generate plans $425M IPO to bankroll antibody's phase 3 asthma trials
Gossamer's stock sinks after phase 3 pulmonary arterial hypertension fail
Gossamer's stock sinks after phase 3 pulmonary arterial hypertension fail
MoonLake's phase 2 arthritis win kicks off pivotal year for IL-17 nanobody
MoonLake's phase 2 arthritis win kicks off pivotal year for IL-17 nanobody
Assessing Myelin Formation and Therapeutic Response Using 3D Organoids
Assessing Myelin Formation and Therapeutic Response Using 3D Organoids
iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson’s and First Enrollment in China’s Randomized MSA Trial for NouvNeu004
iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson’s and First Enrollment in China’s Randomized MSA Trial for NouvNeu004
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page